Research Topics
| Dipak PanigrahySummaryAffiliation: Harvard University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in miceDipak Panigrahy
Vascular Biology Program, Children s Hospital Boston, Boston, Massachusetts, USA
J Clin Invest 122:178-91. 2012..Thus, our data indicate a central role for EETs in tumorigenesis, offering a mechanistic link between lipid signaling and cancer and emphasizing the critical importance of considering possible effects of EET-modulating drugs on cancer...- Cytochrome P450-derived eicosanoids: the neglected pathway in cancerDipak Panigrahy
Vascular Biology Program, Children s Hospital Boston, Boston, MA, USA
Cancer Metastasis Rev 29:723-35. 2010..In this review, the emerging role in cancer of cytochrome P450 metabolites, notably 20-HETE and EETs, are discussed... 
EET signaling in cancerDipak Panigrahy
Vascular Biology Program, Boston Children s Hospital, Division of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Cancer Metastasis Rev 30:525-40. 2011..In this review, the emerging role of EET signaling in angiogenesis, inflammation, and cancer is discussed...- PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibitionDipak Panigrahy
Vascular Biology Program, Children s Hospital, Department of Surgery, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 105:985-90. 2008..Our results provide a mechanistic rationale for evaluating the clinical benefits of PPARalpha agonists in cancer treatment, alone and in combination with other therapies... - PPARalpha deficiency in inflammatory cells suppresses tumor growthArja Kaipainen
Vascular Biology Program, Department of Surgery, Children s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
PLoS ONE 2:e260. 2007..These findings suggest that the absence of PPARalpha activity renders inflammatory infiltrates tumor suppressive and, thus, may provide a target for inhibiting tumor growth by modulating stromal processes, such as angiogenesis... - Regulation of inflammation in cancer by eicosanoidsEmily R Greene
Vascular Biology Program, Children s Hospital Boston, Harvard Medical School, Boston, MA, USA
Prostaglandins Other Lipid Mediat 96:27-36. 2011..Eicosanoids may represent a missing link between inflammation and cancer and thus could serve as therapeutic target(s) for inhibiting tumor growth... 
PPARgamma as a therapeutic target for tumor angiogenesis and metastasisDipak Panigrahy
Vascular Biology Program, Children's Hospital, Department of Surgery, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer Biol Ther 4:687-93. 2005..This will be paramount if the potent biological activity of PPARgamma agonists are to be harnessed for cancer therapy...- Therapeutic potential of thiazolidinediones as anticancer agentsDipak Panigrahy
Children's Hospital, Research Building, Floor 12, Boston, MA, USA
Expert Opin Investig Drugs 12:1925-37. 2003..Further studies suggest that TZDs may be effective in prevention of certain cancers and in the treatment of cancer as adjuvant therapy... - Inhibition of neuroblastoma cell proliferation with omega-3 fatty acids and treatment of a murine model of human neuroblastoma using a diet enriched with omega-3 fatty acids in combination with sunitinibCarmen M Barnes
Vascular Biology Program, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts, USA
Pediatr Res 71:168-78. 2012..We investigated the use of dietary omega-3 (ω-3) polyunsaturated fatty acids (PUFAs) in the treatment of neuroblastoma both as a sole agent and in combination with sunitinib, a broad-spectrum tyrosine kinase receptor inhibitor... - PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesisDipak Panigrahy
Surgical Research Laboratory, Children's Hospital, Department of Surgery, Harvard Medical School, Boston, Massachusetts, USA
J Clin Invest 110:923-32. 2002..These results suggest that PPARgamma ligands may be useful in treating angiogenic diseases such as cancer by inhibiting angiogenesis... - Adipose tissue mass can be regulated through the vasculatureMaria A Rupnick
Division of Cardiovascular Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 99:10730-5. 2002..We conclude that adipose tissue mass is sensitive to angiogenesis inhibitors and can be regulated by its vasculature... - The anti-angiogenic peptide, loop 6, binds insulin-like growth factor-1 receptorCecilia A Fernandez
Vascular Biology Program, Children s Hospital Boston, Boston, Massachusetts 02115, USA
J Biol Chem 285:41886-95. 2010.... - Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)Anette Duensing
Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
Oncogene 23:3999-4006. 2004.... - Broad spectrum antiangiogenic treatment for ocular neovascular diseasesOfra Benny
Vascular Biology Program and Department of Surgery, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts, United States of America
PLoS ONE 5:. 2010..Several unique properties make Lodamin especially beneficial for ophthalmic use. Our results support the concept that broad spectrum antiangiogenic drugs are promising agents for AMD treatment and prevention...
Research Grants
- Control of cancer and metastasis by endothelial-derived epoxyeicosatrienoic acidsDipak Panigrahy; Fiscal Year: 2010..Conversely, blocking the EET pathway may offer a new strategy to block tumor blood vessels and, hence, help combat cancer. Thus, novel drugs which block EETs will be tested in preclinical trials to confirm their activity. ..